What is it about?
Role of Proteasome in the Development of Chemoresistance in Multiple Myeloma effectively conveys the focus of the research, which is to explore how the proteasome contributes to the resistance of multiple myeloma cells to chemotherapy.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Understanding the role of the proteasome in the development of chemoresistance in multiple myeloma is crucial for advancing treatment strategies and improving patient outcomes. Proteasome inhibitors, such as bortezomib, are integral to MM therapy due to their ability to disrupt protein degradation pathways essential for tumor cell survival.
Perspectives
The proteasome's involvement in chemoresistance in MM is multifaceted, encompassing structural alterations, microenvironmental influences, and compensatory survival pathways. A comprehensive understanding of these mechanisms is essential for developing novel therapeutic strategies aimed at overcoming resistance and improving the efficacy of proteasome inhibitors in MM treatment.
Dr.Ramakrishnan Veerabathiran
Chettinad Health City
Read the Original
This page is a summary of: Role of proteasome in the development of chemoresistance in multiple myeloma, January 2025, Elsevier,
DOI: 10.1016/b978-0-443-30098-1.00026-4.
You can read the full text:
Contributors
The following have contributed to this page
